Iran has started the second phase of the injection of its domestically-developed coronavirus vaccine to volunteers, further consolidating its steps towards a better containment of the flu-like pathogen.
Dr. Hamed Hosseini, director of the Clinical Trial Center of Tehran University of Medical Sciences, made the announcement on Monday, saying the second phase of the injection was approved last night for the volunteers of the first human study of the Iranian vaccine dubbed “Coviran Barekat.”
“The Iranian vaccine will be injected to four other volunteers by the end of this week, and the results of the second phase will be announced to the monitoring committee early next week,” Hosseini said.
Iran began the first phase in the human trial of the homegrown COVID-19 vaccine on December 29 after successfully completing the initial steps, including tests on animals, and obtaining necessary approvals.
The vaccine, produced by Iranian experts at the Headquarters for Executing the Order of Imam Khomeini, was administered to three volunteers at a ceremony in Tehran.
Pointing to the general condition of the first three volunteers for the Iranian vaccine tested last month, Hosseini said those individuals are “fine and everything is going well.”
The director of the Clinical Trial Center of Tehran University of Medical Sciences said the whole period of the vaccination of volunteers for a phase one clinical trial for the Iranian vaccine will continue for two months and that a total of 56 volunteers would receive shots in this phase.
The vaccine, dubbed Coviran Barekat, is named after the pharmaceutical group that developed the vaccine against the coronavirus pandemic and is made of a virus that is weakened or killed by chemicals.